Taiwan c.bank raises GDP forecast, may hike rates in 2022

Author of the article: Reuters Liang-Sa Loh and Yimou Lee TAIPEI — Taiwan’s central bank revised up the island’s 2021 growth outlook on Thursday as strong exports bolstered its trade-reliant economy that has boomed on technology demand, and said it would likely tighten policy next year by raising rates. Companies in Taiwan, home to major…
Taiwan c.bank raises GDP forecast, may hike rates in 2022

Author of the article:

Reuters

Liang-Sa Loh and Yimou Lee

TAIPEI — Taiwan’s central bank revised up the island’s 2021 growth outlook on Thursday as strong exports bolstered its trade-reliant economy that has boomed on technology demand, and said it would likely tighten policy next year by raising rates.

Companies in Taiwan, home to major chip firms like Taiwan Semiconductor Manufacturing Co Ltd (TSMC), have benefited from laptop and tablet demand to support the work-and-study-from-home trend during the pandemic, as well as a global shortage of microchips.

The central bank raised its 2021 estimate for gross domestic product (GDP) growth to 6.03% from a 5.75% forecast in September, and kept the benchmark discount rate at a record low of 1.125%, as expected by all 25 economists in a Reuters poll.

Bank governor Yang Chin-long told reporters the economy was not overheating, inflation was in a controllable range and that they were paying attention to rate rise decisions by major economies.

The rate cut last year was to help Taiwan’s smaller firms, and their progress would help signal the future rate direction, he added.

“If their recovery is going well, then that’s a good opportunity to raise it up again,” Yang said, adding it theoretically could go back to where it was before being cut in March of last year at 1.375%.

Asked about the likelihood of a rate hike next year, Yang said “there is a possibility.”

The bank “definitely will be heading towards the direction of tightening,” he added.

Taiwan’s decision to hold fire on rates comes after the U.S. Federal Reserve on Wednesday said it would end its pandemic-era bond purchases in March and pave the way for three quarter-percentage-point interest rate hikes by the end of 2022.

Kevin Wang, an economist at Taishin Securities Investment Advisory Co, said any rate rise next year would likely only come after the Fed moved first.

“I expect Taiwan’s central bank is more likely to raise the rate in the second half, and maybe do so twice,” he said.

Taiwan was one of the few Asian economies to grow in pandemic-hit 2020, expanding 3.11% that year – faster than China – after 2.71% growth in 2019.

GDP expanded in the third quarter of 2021 by 3.7% versus the year ago period, down from 7.43% in the second quarter, pulled lower by a partial lockdown to prevent domestic COVID-19 infections from spreading, but policy makers have predicted 6% or more growth for the full year because of the export surge.

For 2022, the bank said it saw GDP expanding 4.03%, compared to a previous prediction of 3.45%.

It has kept its policy rate unchanged at every quarterly meeting since cutting it in March 2020. (Reporting by Liang-sa Loh and Yimou Lee; Additional reporting by Emily Chan; Writing by Ben Blanchard; Editing by Ana Nicolaci da Costa and Christian Schmollinger)

Financial Post Top Stories

Sign up to receive the daily top stories from the Financial Post, a division of Postmedia Network Inc.

By clicking on the sign up button you consent to receive the above newsletter from Postmedia Network Inc. You may unsubscribe any time by clicking on the unsubscribe link at the bottom of our emails. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published.

Related Posts
China approves use of Pfizer’s COVID drug Paxlovid
Read More

China approves use of Pfizer’s COVID drug Paxlovid

Author of the article: BEIJING — China’s medical products regulator said on Saturday it has given conditional approval for Pfizer’s COVID-19 treatment Paxlovid, making it the first oral anti-coronavirus pill approved in the country to treat the disease. The National Medical Products Administration said Paxlovid has obtained conditional approval to treat adults who have mild…
German manufacturing bottlenecks ease in January, Ifo says
Read More

German manufacturing bottlenecks ease in January, Ifo says

Author of the article: BERLIN — The number of German manufacturing companies reporting bottlenecks and problems procuring intermediate products and raw materials eased to 67.3% in January from 81.9% in December, the Ifo economic institute said on Monday. “Despite this development, companies still have much to worry about,” Ifo economist Klaus Wohlrabe said in a…